Transcriptome profiling further highlighted SHH pathway activation in MPNST-G1, with computational network analysis-based drug screen suggesting the SMO inhibitors are one of the top drug classes for treatment of MPNST-G1. This evidence concerns the gene SHH and malignant peripheral nerve sheath tumor.